Cargando…

The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases

OBJECTIVES: In our previous studies we reported a panel of 24 miRNAs that allowed discrimination between blood of lung tumor patients independent of the histological subtype and blood of healthy controls with an accuracy of 95.4% [94.9%-95.9%]. Here, we now separately analyzed the miRNA expression i...

Descripción completa

Detalles Bibliográficos
Autores principales: Leidinger, Petra, Backes, Christina, Blatt, Michael, Keller, Andreas, Huwer, Hanno, Lepper, Philipp, Bals, Robert, Meese, Eckart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156643/
https://www.ncbi.nlm.nih.gov/pubmed/25175044
http://dx.doi.org/10.1186/1476-4598-13-202
_version_ 1782333769708994560
author Leidinger, Petra
Backes, Christina
Blatt, Michael
Keller, Andreas
Huwer, Hanno
Lepper, Philipp
Bals, Robert
Meese, Eckart
author_facet Leidinger, Petra
Backes, Christina
Blatt, Michael
Keller, Andreas
Huwer, Hanno
Lepper, Philipp
Bals, Robert
Meese, Eckart
author_sort Leidinger, Petra
collection PubMed
description OBJECTIVES: In our previous studies we reported a panel of 24 miRNAs that allowed discrimination between blood of lung tumor patients independent of the histological subtype and blood of healthy controls with an accuracy of 95.4% [94.9%-95.9%]. Here, we now separately analyzed the miRNA expression in blood of non-small cell lung cancer (NSCLC), including squamous cell lung cancer and adenocarcinoma, and small cell lung cancer (SCLC) patients. PATIENTS AND METHODS: In total, we examined the expression levels of 1,205 miRNAs in blood samples from 20 patients from each of the three histological groups and determined differentially expressed miRNAs between histological subtypes and metastatic and non-metastatic lung cancer. We further determined the overlap of miRNAs expressed in each subgroup with the 24-miRNA signature of lung tumor patients. RESULTS: Based on a raw p-value < 0.05, only 18 blood-borne miRNAs were differentially expressed between patients with adenocarcinoma and with squamous cell lung carcinoma, 11 miRNAs between adenocarcinoma and SCLC, and 2 between squamous cell lung carcinoma and SCLC. Likewise, the comparison based on a fold change of 1.5 did not reveal major differences of the blood-borne miRNA expression pattern between NSCLC and SCLC. In addition, we found a large overlap between the blood-borne miRNAs detected in the three histological subgroups and the previously described 24-miRNA signature that separates lung cancer patients form controls. We identified several miRNAs that allowed differentiating between metastatic and non-metastatic tumors both in blood of patients with adenocarcinoma and in blood of patients with SCLC. CONCLUSION: There is a common miRNA expression pattern in blood of lung cancer patients that does not allow a reliable further subtyping into NSCLC or SCLC, or into adenocarcinoma and squamous cell lung cancer. The previously described 24-miRNA signature for lung cancer appears not primarily dependent on histological subtypes. However, metastatic adenocarcinoma and SCLC can be predicted with 75% accuracy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1476-4598-13-202) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4156643
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41566432014-09-07 The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases Leidinger, Petra Backes, Christina Blatt, Michael Keller, Andreas Huwer, Hanno Lepper, Philipp Bals, Robert Meese, Eckart Mol Cancer Research OBJECTIVES: In our previous studies we reported a panel of 24 miRNAs that allowed discrimination between blood of lung tumor patients independent of the histological subtype and blood of healthy controls with an accuracy of 95.4% [94.9%-95.9%]. Here, we now separately analyzed the miRNA expression in blood of non-small cell lung cancer (NSCLC), including squamous cell lung cancer and adenocarcinoma, and small cell lung cancer (SCLC) patients. PATIENTS AND METHODS: In total, we examined the expression levels of 1,205 miRNAs in blood samples from 20 patients from each of the three histological groups and determined differentially expressed miRNAs between histological subtypes and metastatic and non-metastatic lung cancer. We further determined the overlap of miRNAs expressed in each subgroup with the 24-miRNA signature of lung tumor patients. RESULTS: Based on a raw p-value < 0.05, only 18 blood-borne miRNAs were differentially expressed between patients with adenocarcinoma and with squamous cell lung carcinoma, 11 miRNAs between adenocarcinoma and SCLC, and 2 between squamous cell lung carcinoma and SCLC. Likewise, the comparison based on a fold change of 1.5 did not reveal major differences of the blood-borne miRNA expression pattern between NSCLC and SCLC. In addition, we found a large overlap between the blood-borne miRNAs detected in the three histological subgroups and the previously described 24-miRNA signature that separates lung cancer patients form controls. We identified several miRNAs that allowed differentiating between metastatic and non-metastatic tumors both in blood of patients with adenocarcinoma and in blood of patients with SCLC. CONCLUSION: There is a common miRNA expression pattern in blood of lung cancer patients that does not allow a reliable further subtyping into NSCLC or SCLC, or into adenocarcinoma and squamous cell lung cancer. The previously described 24-miRNA signature for lung cancer appears not primarily dependent on histological subtypes. However, metastatic adenocarcinoma and SCLC can be predicted with 75% accuracy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1476-4598-13-202) contains supplementary material, which is available to authorized users. BioMed Central 2014-08-30 /pmc/articles/PMC4156643/ /pubmed/25175044 http://dx.doi.org/10.1186/1476-4598-13-202 Text en © Leidinger et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Leidinger, Petra
Backes, Christina
Blatt, Michael
Keller, Andreas
Huwer, Hanno
Lepper, Philipp
Bals, Robert
Meese, Eckart
The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases
title The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases
title_full The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases
title_fullStr The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases
title_full_unstemmed The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases
title_short The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases
title_sort blood-borne mirna signature of lung cancer patients is independent of histology but influenced by metastases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156643/
https://www.ncbi.nlm.nih.gov/pubmed/25175044
http://dx.doi.org/10.1186/1476-4598-13-202
work_keys_str_mv AT leidingerpetra thebloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT backeschristina thebloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT blattmichael thebloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT kellerandreas thebloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT huwerhanno thebloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT lepperphilipp thebloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT balsrobert thebloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT meeseeckart thebloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT leidingerpetra bloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT backeschristina bloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT blattmichael bloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT kellerandreas bloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT huwerhanno bloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT lepperphilipp bloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT balsrobert bloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases
AT meeseeckart bloodbornemirnasignatureoflungcancerpatientsisindependentofhistologybutinfluencedbymetastases